Virtu Financial LLC Cuts Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Virtu Financial LLC cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 16.4% in the 4th quarter, HoldingsChannel reports. The firm owned 4,430 shares of the medical research company’s stock after selling 870 shares during the period. Virtu Financial LLC’s holdings in IQVIA were worth $870,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in IQV. Smith Group Asset Management LLC purchased a new position in IQVIA in the fourth quarter worth $1,616,000. Nordea Investment Management AB increased its position in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares during the last quarter. Hickory Asset Management Inc. purchased a new position in shares of IQVIA during the 4th quarter valued at about $941,000. Fifth Third Bancorp boosted its stake in IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after buying an additional 1,521 shares in the last quarter. Finally, Graphene Investments SAS grew its position in IQVIA by 22.0% during the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock valued at $2,948,000 after acquiring an additional 2,700 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on IQV shares. Citigroup cut their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Stephens initiated coverage on IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. Finally, JPMorgan Chase & Co. cut their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Stock Performance

Shares of IQVIA stock opened at $186.35 on Tuesday. The business has a fifty day simple moving average of $194.58 and a two-hundred day simple moving average of $207.73. The firm has a market capitalization of $32.86 billion, a P/E ratio of 24.85, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12 month low of $179.28 and a 12 month high of $254.54.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.